摘要
Abstract
Objective:To explore the clinical application value of the Tislelizumab combined with Capecitabine treatment regimen in patients with advanced colorectal cancer.Method:A total of 76 patients with advanced colorectal cancer who were treated in the Department of Oncology of Huhhot First Hospital from March 2022 to July 2023 were included.They were divided into the study group and the control group by random number table method,with 38 cases in each group.Patients in the study group received the treatment regimen of Tislelizumab combined with Capecitabine,while patients in the control group were treated with Capecitabine monotherapy.The course of treatment was 21 days,and two consecutive courses of treatment were administered.The clinical efficacy indicators,levels of tumor marker,levels of angiogenesis-related factors,occurrence of adverse reactions,and progression-free survival of the two groups of patients were recorded and compared.Result:After treatment,the objective response rate(ORR)and disease control rate(DCR)of the study group were higher than those of the control group(P<0.05).In terms of tumor marker levels,after treatment,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)and carbohydrate antigen 242(CA242)in the study group were all lower than those in the control group(P<0.05).In terms of the levels of angiogenesis-related factors,after treatment,the levels of vascular endothelial growth factor(VEGF),insulin-like growth factor-1(IGF-1)and basic fibroblast growth factor(bFGF)in the study group were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Survival analysis showed that the 12-month progression-free survival rate of patients in the study group was higher than that in the control group(P<0.05).Conclusion:The treatment regimen of Tislelizumab combined with Capecitabine can significantly improve the clinical efficacy of patients with advanced colorectal cancer,effectively reduce the levels of tumor markers,inhibit tumor angiogenesis,prolong progression-free survival,and does not increase the incidence of adverse reactions.关键词
程序性细胞死亡蛋白-1抑制剂/替雷利珠单抗/卡培他滨/晚期结直肠癌/肿瘤标志物/无进展生存期Key words
Programmed cell death protein-1 inhibitors/Tislelizumab/Capecitabine/Advanced colorectal cancer/Tumor markers/Progression-free survival分类
医药卫生
